LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

The rally came despite a broader market volatility during the period, largely due to global trade worries over the United States’ imposition of tariffs against its trading partners, with China ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

The FDA has accepted the New Drug Application for doravirine/islatravir for adults with virologically-suppressed HIV-1 infection.

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...